Title of project or programme

Natural Antibodies against phosphorylcholine in cardiovascular disease and Alzheimer’s disease

Principal Investigators of project/programme grant
Title Forname Surname Institution Country
Professor Johan Department of Medicine, Karolinska Institute  Sweden
Professor emeritus Ulf Institute of Environmental Medicine, Karolinska Institute VU Medical Centre  Sweden
Chief Executive Officer Carina Schmidt Athera Biotechnologies AB  Sweden
Address of institution of lead PI
Institution Department of Medicine, Karolinska Institute
Street Address De Geersgatan 16
City Stockholm
Postcode 115 29
Country
  • Sweden
Source of funding information

VINNOVA

Total sum awarded (Euro)

560000

Start date of award

01-07-2009

Total duration of award in months

36

The project/programme is most relevant to
  • Alzheimer’s disease and other dementias
Keywords

atherosclerosis, natural antibodies, immunization, Alzheimer’s disease, inflammation

Research abstract in English

Chronic inflammatory diseases like atherosclerosis and its consequences cardiovascular disease (CVD) in the form of stroke and myocardial infarction are dominating health problems in the western world and increasingly in the developing countries. Also Alzheimer’s disease has a relation to inflammation, and is another major health problem. We have demonstrated that oxidized phospholipids (oxPL) can be central underlying factors and that natural antibodies against specific lipid-moieties (especially phosphorylcholine, PC) on them are protection factors where low levels leads to raised risk for CVD. We have alsodemonstrated that a protein, Annexin A5, also can play an important role to inhibit oxPL, and inflammatory reactions in the arteries. We therefore propose a novel paradism for chronic inflammatory diseases, where an underactivated natural immune defence against PC (and other oxPL epitopes), decrease the protection against oxPL.the purpose with the project is to clarify: which role do these antibodies play as novel diagnostic markers; which is the cause ofthe abovementioned immune deficiency state; how can the immune system cause these diseases. The goal is to develop novel immunological diagnostics and treatment against oxPL in the form of active immunisation and/or vaccination. We expect to demonstrate underlying mechanisms regulating natural antibodies against PC and other oxPL and how they exert their effects. Further, which role does oxPL and antibodies against them play for incidence and development of chronic inflammatory diseases including CVD, Alzheimer’s disease and also rheumatic disease like SLE and RA. We expect to develop novel therapeutic principles for treatment of chronic inflammatory diseases by passive and/or active immunisation to raise antibody levels. Another major candidate is Annexin A5, which also interacts with these atherogenic oxPL.

Lay Summary

Types: Investments > €500k
Member States: Sweden
Diseases: Alzheimer's disease & other dementias
Years: 2011
Database Categories: N/A
Database Tags: N/A

Export as PDF